https://doi.org/10.55788/4aa72181
NRTX-1001 cells are embryonic stem cells differentiated into pallial medial ganglionic eminence-type GABAergic interneurons. They are post-mitotic and do not proliferate. In mice with kainate-induced mesiotemporal sclerosis, implantation of these cells resulted in 66% of mice being free of focal seizures. The interneuron cell therapy also reduced hippocampal damage and increased survival in these mice.
A first-in-human, phase 1/2 clinical trial (NCT05135091) investigates whether implantation of human NRTX-1001 neural cell therapy can lead to seizure control in drug-resistant mesial temporal lobe epilepsy [1]. Participants receive immunosuppression starting 1 week before surgery and tapered after 1 year. Treatment consists of a stereotactic one-time injection along the long axis of the hippocampus with intraoperative MRI imaging. The trial follows a 2-stage design: in the open-label phase 1, 10 participants receive low- or high-dose treatments. In the double-blind phase 2, 20 participants receive cell implantation and 10 participants sham treatment. The primary endpoint is the incidence of serious or severe adverse events. Key secondary endpoints include a reduction in seizures and responder rate. Participants are between 16 and 65 years of age, have focal seizures clinically defined as temporal lobe epilepsy, and have failed to achieve seizure control on at least 2 anti-seizure medications.
Prof. David Spencer (Oregon Health & Science University, OR, USA) presented the results of the first 2 enrolled participants [1]. The first participant was a 26-year-old man who had had seizures since the age of 19. Before treatment, he averaged 32 seizures per month and treatment with 4 anti-seizure medications had previously failed. At 8 months follow-up after NRTX-1001 cell therapy, the participant had a 93% seizure reduction from baseline and had not had a focal awareness-impaired seizure since the first month.
The second participant was a 59-year-old woman who had had seizures since she was 50, had previously failed on 3 anti-seizure medications, and averaged 14 seizures a month. After 2 months of follow-up after NRTX-1001 cell therapy, she had experienced just 1 seizure.
The observed adverse events after surgery were non-serious and of mild severity in both participants. None of the adverse events were deemed related to cell therapy, some to immunosuppression. Prof. Spencer said he was excited about the first results of this novel therapy.
- First-in-human trial of NTRX-1001 GABAergic interneuron cell therapy for treatment of focal epilepsy - emerging clinical trial results. ES1.007, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Lecanemab may slow decline of cognition and function in Alzheimer’s Disease Next Article
Seizure forecasting and detection with wearable devices are feasible »
« Lecanemab may slow decline of cognition and function in Alzheimer’s Disease Next Article
Seizure forecasting and detection with wearable devices are feasible »
Table of Contents: AAN 2023
Featured articles
Letter from the Editor
Positive results for hereditary transthyretin-mediated amyloid polyneuropathy
Infectious Diseases
Allogenic T-cell-based immunotherapy for PML in development
Cognitive Impairment and Dementia
Lecanemab may slow decline of cognition and function in Alzheimer’s Disease
Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease
Epilepsy
Seizure forecasting and detection with wearable devices are feasible
Encouraging first results of GABAergic interneurons implants for focal epilepsy
Headache and Migraine
Lecture on migraine: from the prodromal phase to future paradigm shifts
Zavegepant nasal spray exhibits good efficacy and safety in acute migraine
A vaccine as a potentially safe and effective immunotherapy against CGRP
Multiple Sclerosis
Teriflunomide prevents conversion to MS in patients with RIS
Gold nanocrystals may be effective as adjunctive MS therapy
Muscle and Neuro-Muscular Disorders
First-ever ALS platform trial reports on outcomes of 4 treatments
Pridopidine for Huntington’s disease fails to meet the primary endpoint
Parkinson's Disease
Continuous levodopa/carbidopa infusion shows favourable safety and efficacy
Unilateral right STN-DBS improves verbal fluency
Stroke
Harnessing the microbiome as a possible stroke treatment
Patients with a large core infarct benefit from thrombectomy
Miscellaneous
Artificial intelligence applications in neurology: seize the moment
Spinal cord stimulation eases painful diabetic neuropathy
EVT improves functional outcomes in Chinese patients with BAO
Severe sleep apnoea associated with white matter hyperintensities
Related Articles
October 30, 2022
Impact of CPAP on cardiac endpoints in OSA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com